Company profile
AIM IMMUNOTECH INC.
AMEX:AIMBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ALFERON N INJECTION | approved | $0.0MQ2 2026 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00215852 | phase2 | terminated | 2005-07-01 | 2009-04-01 | AIM ImmunoTech Inc. | A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects |
| NCT05494697 | phase2 | suspended | 2027-08-01 | 2031-02-01 | AIM ImmunoTech Inc. | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC |
| NCT01591473 | phase1_2 | terminated | 2012-04-01 | 2014-09-01 | AIM ImmunoTech Inc. | Safety Study of FluMist With and Without Ampligen |
| NCT00035581 | phase2 | terminated | 2001-05-01 | 2005-09-01 | AIM ImmunoTech Inc. | Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART |
| NCT00215826 | phase2 | completed | 2004-11-01 | 2006-04-01 | AIM ImmunoTech Inc. | Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 103158 | 1989-10-10 | BLA | AIM IMMUNOTECH INC. | |||||
Loading… | ||||||||